Dr. Reddy's Laboratories Launches Testosterone Gel, 1.62% in the US Market
8 May 2019 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY has launched of Testosterone Gel 1.62%, a therapeutic equivalent generic version of AndroGel (testosterone gel) 1.62%, approved by the US Food and Drug Administration (USFDA), the company said.

The AndroGel (testosterone gel) brand and generic had US sales of approximately USD 815.6m MAT for the most recent twelve months ending in February 2019 according to IQVIA Health.

Dr. Reddy's Testosterone Gel 1.62% (20.25 mg/1.25 g pump actuation) is available in a net quantity of 88 g pump which dispenses 20.25 mg of testosterone per actuation. Each metered-dose pump is capable of dispensing 60 metered pump actuations.

AndroGel is a trademark of AbbVie Inc.

Dr. Reddy's Laboratories is an integrated pharmaceutical company, with a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.